Development and clinical data from the European Healthcare company AOP Orphan Pharmaceuticals AG form the basis of introducing the new drug Landiolol in Canada for rapid heart rate control in the hospital setting. Trimedic Therapeutics Inc will immediately become the Canadian market authorization holder and exclusive distributor.

The innovative ultra-short acting beta-blocker is administered intravenously. It fulfills an unmet medical need: the administration of this medicinal agent in life-critical conditions, where it is desirable to safely and rapidly reduce heart rate with minimal effect in blood pressure and inotropy (e.g., patients in sepsis, patients with heart failure, patients with peri-operative atrial fibrillation or supraventricular tachycardia).

AOP Orphan Pharmaceuticals AG (AOP Orphan) has been conducting several clinical studies to confirm further the critical benefits of a super-selective, short-acting, and rapidly reversible beta-blocker the breadth of the utility of Landiolol for patients in acute care. According to the Canadian Institute for Health Information, stroke, heart failure, heart attacks, and sepsis are four of the six leading causes of hospital deaths. “Our new partner Trimedic Therapeutics Inc can build on our expertise. We are happy to be able to support hospitalized patients in Canada through this strong partnership and to bring this innovative European medicine to Canada,” says Andreas Steiner, CEO of AOP Orphan.

“We are always looking for products that may offer a unique delivery and greater benefit to the physician, the health system, and especially the patient. Landiolol will be the first beta-blocker introduced in Canada in more than 20 years. The actual agreement with AOP Orphan meets our needs in this regard,” comments Marty Tenenbaum, president and founder of Trimedic Therapeutics Inc of Toronto, Canada.